Difference between revisions of "Vulvar cancer"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "===Older===" to "")
m
 
(6 intermediate revisions by 3 users not shown)
Line 11: Line 11:
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
 
=Guidelines=
 
=Guidelines=
−
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.'''
+
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
−
==[https://www.nccn.org/ NCCN]==
+
==NCCN==
−
*[https://www.nccn.org/professionals/physician_gls/pdf/vulvar.pdf NCCN Guidelines - Vulvar Cancer]
+
*[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1476 NCCN Guidelines - Vulvar Cancer]
−
 
+
**'''2017:''' Koh et al. [https://doi.org/10.6004/Jnccn.2017.0008 Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.] [https://pubmed.ncbi.nlm.nih.gov/28040721/ PubMed]
−
*'''2017:''' [https://doi.org/10.6004/jnccn.2017.0008 Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology] [https://pubmed.ncbi.nlm.nih.gov/28040721/ PubMed]
 
  
 
=Neoadjuvant therapy=
 
=Neoadjuvant therapy=
Line 22: Line 21:
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:63d249|Variant=1}}===
 
===Regimen {{#subobject:63d249|Variant=1}}===
−
{| class="wikitable" style="width: 40%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
−
!style="width: 25%"|Study
+
!style="width: 33%"|Study
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
 
|[https://doi.org/10.1016/j.ygyno.2011.11.003 Moore et al. 2011]
 
|[https://doi.org/10.1016/j.ygyno.2011.11.003 Moore et al. 2011]
 +
|2005-01-19 to 2009-09-21
 
| style="background-color:#91cf61" |Phase 2
 
| style="background-color:#91cf61" |Phase 2
 
|-
 
|-
Line 34: Line 35:
 
*[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22, 29, 36, 43
 
*[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22, 29, 36, 43
 
====Radiotherapy====
 
====Radiotherapy====
−
*Concurrent [[External_beam_radiotherapy|radiation therapy]] 1.8 Gy per day on days 1 to 5, 8 to 12, 15 to 19, 22 to 26, 29 to 33, 36 to 40, 43, 44 (32 fractions, for a dose of 57.6 Gy)
+
*Concurrent [[External_beam_radiotherapy|radiation therapy]] 180 cGy per day on days 1 to 5, 8 to 12, 15 to 19, 22 to 26, 29 to 33, 36 to 40, 43, 44 (32 fractions, for a dose of 5760 cGy)
 
'''6.5-week course'''
 
'''6.5-week course'''
 
</div>
 
</div>
Line 48: Line 49:
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:723bf0|Variant=1}}===
 
===Regimen {{#subobject:723bf0|Variant=1}}===
−
{| class="wikitable" style="width: 40%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
−
!style="width: 25%"|Study
+
!style="width: 33%"|Study
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731017/ Witteveen et al. 2009]
+
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731017/ Witteveen et al. 2009 (EORTC 55985)]
 +
|2001-02 to 2004-12
 
|style="background-color:#91cf61"|Phase 2
 
|style="background-color:#91cf61"|Phase 2
 
|-
 
|-
Line 62: Line 65:
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
# Witteveen PO, van der Velden J, Vergote I, Guerra C, Scarabeli C, Coens C, Demonty G, Reed N; [[Study_Groups#EORTC|EORTC]]. Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer--Gynaecological Cancer Group). Ann Oncol. 2009 Sep;20(9):1511-6. Epub 2009 Jun 1. [https://doi.org/10.1093/annonc/mdp043 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731017/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/19487487/ PubMed]
+
# '''EORTC 55985:''' Witteveen PO, van der Velden J, Vergote I, Guerra C, Scarabeli C, Coens C, Demonty G, Reed N; [[Study_Groups#EORTC|EORTC]]. Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer--Gynaecological Cancer Group). Ann Oncol. 2009 Sep;20(9):1511-6. Epub 2009 Jun 1. [https://doi.org/10.1093/annonc/mdp043 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731017/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/19487487/ PubMed]
 
[[Category:Vulvar cancer regimens]]
 
[[Category:Vulvar cancer regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
 
[[Category:Gynecologic cancers]]
 
[[Category:Gynecologic cancers]]

Latest revision as of 13:04, 30 June 2024

Back to Top

Section editor
Brown-alaina.jpeg
 Alaina J. Brown, MD, MPH
Vanderbilt University
Nashville, TN, USA
LinkedIn
2 regimens on this page
2 variants on this page


Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

NCCN

Neoadjuvant therapy

Cisplatin & RT

Cisplatin & RT: Cisplatin & Radiation Therapy

Regimen

Study Dates of enrollment Evidence
Moore et al. 2011 2005-01-19 to 2009-09-21 Phase 2

Chemotherapy

Radiotherapy

  • Concurrent radiation therapy 180 cGy per day on days 1 to 5, 8 to 12, 15 to 19, 22 to 26, 29 to 33, 36 to 40, 43, 44 (32 fractions, for a dose of 5760 cGy)

6.5-week course

Subsequent treatment

References

  1. Moore DH, Ali S, Koh WJ, Michael H, Barnes MN, McCourt CK, Homesley HD, Walker JL. A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Mar;124(3):529-33. Epub 2011 Nov 9. link to original article contains dosing details in abstract PubMed

Locally advanced or metastatic disease

Due to its relative rarity, there are very few prospective trials in advanced and metastatic vulvar cancer. In clinical practice, many adopt regimens from the cervical cancer literature; see the cervical cancer page for those regimens.

Paclitaxel monotherapy

Regimen

Study Dates of enrollment Evidence
Witteveen et al. 2009 (EORTC 55985) 2001-02 to 2004-12 Phase 2

Chemotherapy

21-day cycle for up to 10 cycles

References

  1. EORTC 55985: Witteveen PO, van der Velden J, Vergote I, Guerra C, Scarabeli C, Coens C, Demonty G, Reed N; EORTC. Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer--Gynaecological Cancer Group). Ann Oncol. 2009 Sep;20(9):1511-6. Epub 2009 Jun 1. link to original article link to PMC article contains dosing details in manuscript PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Vulvar_cancer&oldid=87869"